One hundred and eighteen subjects with familial adenomatous polyposis (FAP) and 80 of their relatives who were at low risk (<0-01) of carrying the FAP gene were scored by one of us (BJ) or by colleagues to assess the frequency of congenital hypertrophy of the retinal pigment epithelium (CHRPE). A CHRPE is defined as an "oval pigmented lesion surrounded by depigmented halo". Seventy five (63-6%) of the FAP cases and one (1P2%) of their relatives had at least one CHRPE. There was no systematic difference in the number of CHRPEs in the left and right eyes so all analyses are based on total number of CHRPEs and the findings were highly correlated (p=0-001 for a test of no correlation). There was also no evidence of any age effect in total number of CHRPEs in affected subjects. In 26 families there was more than one subject affected with FAP. There was a significant common family effect with respect to CHRPE expression for total number of CHRPEs with an F statistic of 1-73 (p=0-02 for a test of no family aggregation) indicating that family members are more similar to each other than to affected subjects from other families. This may indicate that specific mutations play a role in determining the number of CHRPEs. Nine affected subjects had intra-abdominal desmoids, and in these the frequency of each of the types of CHRPE was no higher (in fact, slightly lower) than the average for affected subjects without desmoids, but this difference was not significant (p > 0 3). ( Med Genet 1994;31:55-58) The occurrence of pigmented lesions of the retina in several affected members of one family with Gardner syndrome was first described by Blair and Trempel in 1980. These retinal lesions have become known as CHRPE (congenital hypertrophy of the retinal pigment epithelium) and are characteristically ovoid or round discrete lesions, 0-1 to 1 0 or more disc Retinal lesions in patients with FAP have been classified into five types, but it is the oval pigmented lesion with a pale halo that is unique to FAP.91 0 Small pigmented black dots in the periphery of the retina, the most common lesion in FAP, also occur in normal subjects, but in these normal subjects more than three lesions are rarely found. ' The difficulty with using the presence or absence of CHRPE as a diagnostic tool in those at risk of FAP stems from the possibility that in some families there is no expression of CHRPE in affected subjects. Various authors have addressed the question of whether there is genetic heterogeneity in FAP with some families expressing CHRPE and some not, or whether there is variability within the same kindred with regard to the expression of CHRPE. Most authors subscribe to the concept of heterogeneity, with about one-quarter of families showing non-expression of CHRPE in affected subjects (15%,7 one third,6 35%12) while other families showed almost 100% expression of CHRPE. A number of authors have found a higher proportion of CHRPE in patients with FAP and with extracolonic features than in those without.'013 Since this question is of great importance when the presence of CHRPE is used as a clinical tool for predictive testing, we set out to determine whether there was genetic heterogeneity with respect to CHRPE in the FAP families ascertained by the Polyposis Registry in London. We have also noted those subjects in whom
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Results
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There was no systematic difference between the left and right eyes of cases (p > 0 14 for all comparisons) so the total number of lesions was computed for each subject by lesion type. Table 2 summarises the distribution of the number of CHRPEs identified by subject status. For each subject the total number of lesions in both eyes is combined. Investigation using linear regression of total number of CHRPEs with age showed no relationship for any of the five types of lesions (p > 0-12 for all comparisons).
Comparisons between the affected FAP patients and their low risk relatives showed highly significant differences, with patients having more CHRPEs on average for each classification (p < 0-00 1 for each comparison).
There was evidence of a within family correlation (p = 002) for the number of type (a) lesions in affected family members. The F statistic from the ANOVA table was 1-73 which implies an intraclass correlation of 0-27. Thus family members are significantly more similar in terms of CHRPE count than nonfamily members, but the similarity is not extensive. Table 3 summarises the frequency of family members with type (a) lesions among the families by the number of affected relat- ives. Of particular note are the three families with three affected members who are CHRPE positive, as well as the family with six CHRPE positive family members out of six affected. The other classifications of CHRPEs showed no evidence of family aggregation. A comparison of the nine FAP patients with desmoids and the 109 without desmoids showed no evidence of a difference for each of the five classifications of CHRPEs (table 4) . Indeed for each of the five classifications, patients with desmoids had fewer CHRPEs than patients without desmoids, but the differences were not significant (p > 0 3 for each comparison).
Discussion
The findings in this study confirm the relative specificity of type (a) lesions (defined as large pigmented lesions with a surrounding halo) to FAP; one or more of these lesions occurred in 64% of gene carriers but in only 1-25% of their low risk relatives. The other CHRPE lesions were seen in an addittional 27% of affected subjects (so that 91% of those affected had a CHRPE of some kind); however, 21% of low risk relatives also had minor (non-(a) type) CHRPE indicating that these lesions are much less specific for FAP.
This information has diagnostic use since identification of CHRPEs of any kind within at risk subjects modifies their risk of being a gene carrier. For instance, consider an at risk relative who has a prior risk of 50% of being a gene carrier. If that person is found to have one or more type (a) lesions, then, because type (a) CHRPEs are so common in carriers and so rare in non-gene carriers, the probability that this person is a gene carrier increases to 98%. Alternatively, if the person has none of the types of CHRPEs examined in this study, then the risk of being a gene carrier is reduced to 19% since only rarely do gene carriers not have any kind of CHRPEs. Only if lesions types (b) to (e) are identified in the absence of type (a) lesions is there limited diagnostic use since approximately an equal number of gene carriers and non-gene carriers fit into this category. Identification of only such lesions then implies that the carrier risk is essentially unchanged from the prior risk. However, concentrating on the type (a) lesions is sufficient to increase the risk to 98% for CHRPE positive subjects and reduce the risk to 27% for CHRPE negative subjects so that inclusion of type (a) CHRPEs is sufficient for most purposes. A further advantage of the type (a) CHRPEs is that for the age groups examined (in this series from 10 years of age), there is no evidence of any variation with age in the number of CHRPEs identified; thus examination for CHRPE in at risk subjects can be taken to be equally reliable.
The estimates obtained in this study could be combined with information from the results of endoscopy and molecular studies in a Bayesian calculation' to provide a final age related risk estimate. We should note, however, in passing, that the usual assumption of the Bayesian calculation is that the various signs under consideration occur independently of each other in gene carriers (and also in nongene carriers) and that before we attempt to include further factors in the Bayesian calculation, their independence should be examined.
We showed a significant within family correlation for the presence of type (a) CHRPEs but the effect was not overwhelming. This suggests that different mutations in the gene causing FAP have differing probabilities of producing CHRPEs but that other factors must also play a role; to date, we do not have any information as to whether these factors are genetic. A natural question to ask concerns the use of this within family correlation for diagnostic purposes to refine further the calculations discussed above. The response is that while there is statistical evidence for the correlation, the effect within individual families is minimal and hence there is no value in including this information. For instance, if we concentrate on those 15 families with only two affected (table 3), we observed two families where neither affected person has type (a) CHRPEs, six where one had CHRPEs, and seven where both had CHRPEs. If there were no within family correlation then the expected numbers of such families would be 1-9 with no CHRPE positive subjects, 6 9 with one CHRPE positive member, and 61 with two CHRPE positive members, which is of course only minimally different from that observed. The majority of the information concerning within family aggregation for presence of CHRPE comes from four families in which all affected family members have CHRPEs; three of these families have three members while the other has six affected. This observation of a family with six CHRPE positive family members should only occur in 7% of families if there were no family aggregation. We might speculate then that at least some of these families have mutations which are more liable to produce CHRPEs; further studies must await the identification of the specific mutations in these and other families.
There have been conflicting reports in the past, some indicating that CHRPEs occur more commonly in subjects with FAP who also have desmoid disease or other extracolonic manifestations than in those without,"3 but others maintaining the opposite.7 In this series, nine affected subjects had serious desmoid disease; CHRPEs did not occur in all of these cases and overall were less common than among FAP subjects without desmoid disease (table 4) . We could therefore find no relationship between desmoid disease and presence of CHRPEs.
